Roth Mkm Reiterates “Buy” Rating for Sanuwave Health (NASDAQ:SNWV)

Sanuwave Health (NASDAQ:SNWV)‘s stock had its “buy” rating restated by investment analysts at Roth Mkm in a research note issued to investors on Monday,Benzinga reports. They currently have a $47.00 price target on the stock, down from their previous price target of $53.00. Roth Mkm’s price target points to a potential upside of 172.31% from the company’s current price.

Several other equities analysts have also commented on SNWV. Weiss Ratings raised Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday. Wall Street Zen lowered Sanuwave Health from a “buy” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $51.00.

Sanuwave Health Stock Down 7.3%

Sanuwave Health stock traded down $1.35 during midday trading on Monday, hitting $17.26. 122,582 shares of the stock were exchanged, compared to its average volume of 63,608. The company has a 50 day moving average price of $24.03 and a two-hundred day moving average price of $29.34. Sanuwave Health has a 1 year low of $16.69 and a 1 year high of $46.58. The firm has a market cap of $148.26 million, a P/E ratio of -108.11 and a beta of 1.32. The company has a debt-to-equity ratio of 10.08, a current ratio of 1.38 and a quick ratio of 1.05.

Sanuwave Health (NASDAQ:SNWV) last issued its quarterly earnings results on Thursday, March 26th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.14). The firm had revenue of $13.09 million during the quarter, compared to the consensus estimate of $13.23 million. Sanuwave Health had a net margin of 26.64% and a negative return on equity of 141.56%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Legal & General Group Plc purchased a new stake in shares of Sanuwave Health in the 2nd quarter valued at approximately $26,000. BNP Paribas Financial Markets acquired a new stake in shares of Sanuwave Health in the second quarter worth $46,000. Farther Finance Advisors LLC acquired a new stake in shares of Sanuwave Health in the third quarter worth $57,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Sanuwave Health during the second quarter valued at $52,000. Finally, Russell Investments Group Ltd. acquired a new position in Sanuwave Health during the third quarter valued at $67,000. 42.53% of the stock is owned by institutional investors and hedge funds.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.